Citadel Advisors
NAGE

Citadel Advisors’s Niagen Bioscience NAGE Stock Holding History

Citadel Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$571K Sell
129,500
-5,900
-4% -$31.9K ﹤0.01% 8979
2025
Q4 		$861K Buy
135,400
+104,500
+338% +$727K ﹤0.01% 7735
2025
Q3 		$288K Sell
30,900
-16,100
-34% -$163K ﹤0.01% 10476
2025
Q2 		$677K Buy
47,000
+32,900
+233% +$325K ﹤0.01% 7916
2025
Q1 		$97.3K Buy
14,100
+8,300
+143% +$52.2K ﹤0.01% 11515
2024
Q4 		$30.8K Sell
5,800
-2,400
-29% -$13.1K ﹤0.01% 12855
2024
Q3 		$29.9K Buy
8,200
+2,100
+34% +$6.61K ﹤0.01% 12441
2024
Q2 		$16.7K Sell
6,100
-200
-3% -$669 ﹤0.01% 12777
2024
Q1 		$21.9K Buy
+6,300
New +$11.7K ﹤0.01% 12946
2023
Q3 		– Sell
-2,100
Closed -$3.3K – 15291
2023
Q2 		$3.3K Sell
2,100
-900
-30% -$1.34K ﹤0.01% 13704
2023
Q1 		$4.59K Buy
3,000
+200
+7% +$356 ﹤0.01% 13942
2022
Q4 		$4.7K Buy
+2,800
New +$4.44K ﹤0.01% 14073
2022
Q3 		– Sell
-22,100
Closed -$37K – 13801
2022
Q2 		$37K Sell
22,100
-28,600
-56% -$55.9K ﹤0.01% 12115
2022
Q1 		$125K Buy
+50,700
New +$139K ﹤0.01% 12051
2021
Q4 		– Sell
-67,400
Closed -$423K – 14952
2021
Q3 		$423K Sell
67,400
-63,300
-48% -$522K ﹤0.01% 10283
2021
Q2 		$1.29M Sell
130,700
-4,900
-4% -$42.7K ﹤0.01% 7683
2021
Q1 		$1.27M Buy
+135,600
New +$1.07M ﹤0.01% 7518

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's NAGE Position: Q1 2026 in Review

Citadel Advisors increased its Niagen Bioscience (NAGE) stake by 35% in Q1 2026, buying an estimated $750K and bringing the position to 530,477 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5756.

Citadel Advisors first reported a position in NAGE in Q1 2018 and has held it in 26 quarters since. The position peaked at $2.49M in Q4 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Citadel Advisors held 530,477 shares of Niagen Bioscience worth $2.34M as of Q1 2026.
  • Citadel Advisors bought 138,937 Niagen Bioscience shares in Q1 2026, an estimated $750K.
  • Niagen Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5756 holding.
  • Citadel Advisors first reported a position in Niagen Bioscience in Q1 2018 and has held it in 26 quarters since.
  • Citadel Advisors's Niagen Bioscience position peaked at $2.49M in Q4 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.